BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. Int J Mol Sci 2021;22:3464. [PMID: 33801659 DOI: 10.3390/ijms22073464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Cháirez-Ramírez MH, de la Cruz-López KG, García-Carrancá A. Polyphenols as Antitumor Agents Targeting Key Players in Cancer-Driving Signaling Pathways. Front Pharmacol 2021;12:710304. [PMID: 34744708 DOI: 10.3389/fphar.2021.710304] [Reference Citation Analysis]
2 Mussa A, Carli D, Cardaropoli S, Ferrero GB, Resta N. Lateralized and Segmental Overgrowth in Children. Cancers (Basel) 2021;13:6166. [PMID: 34944785 DOI: 10.3390/cancers13246166] [Reference Citation Analysis]
3 Yang H, Li Q, Su M, Luo F, Liu Y, Wang D, Fan Y. Design, synthesis, and biological evaluation of novel 6-(pyridin-3-yl) quinazolin-4(3H)-one derivatives as potential anticancer agents via PI3K inhibition. Bioorg Med Chem 2021;46:116346. [PMID: 34403956 DOI: 10.1016/j.bmc.2021.116346] [Reference Citation Analysis]
4 Guney Eskiler G, Ozturk Sezgin M. Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells. Cell Signal 2021;91:110229. [PMID: 34958867 DOI: 10.1016/j.cellsig.2021.110229] [Reference Citation Analysis]